AGA Backs Fecal Microbiota-Based Therapies for Recurrent C. Diff
The American Gastroenterological Association (AGA) endorsed the use of fecal microbiota-based therapies for recurrent Clostridioides difficile infections (CDIs) in new guideline recommendations, but advised against such therapies for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The guideline panel first noted that immunocompetent adults with recurrent CDIs should receive fecal microbiota-based therapies upon completion […]
Oral Microbiome Therapy Tied to Low Recurrence of C. Diff
A potential first-in-class investigational microbiome therapeutic, SER-109, was safe and observed to sustain low Clostridioides difficile (C. diff) recurrence rates for adults, according to the phase III, single-arm ECOSPOR IV study. Recurrence of C. diff infections occurred in 8.7% of patients at week 8 after receiving a short course of capsules containing purified Firmicutes bacteria […]